

HealthSouth is the nation's largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated and discharged, revenues, and number of hospitals.



## Third Quarter 2014 Earnings Call

October 28, 2014

Supplemental Slides

**HEALTHSOUTH**<sup>®</sup>

## Forward-Looking Statements

*The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect our current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, development activities, dividend strategies, repurchases of securities, effective tax rates, financial performance, and business model. These estimates, projections and other forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material.*

*There can be no assurance that any estimates, projections or forward-looking information will be realized.*

*All such estimates, projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly update or revise the information contained herein.*

*You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2013, and the Form 10-Q for the quarters ended March 31, 2014, June 30, 2014, and September 30, 2014, when filed, and in other documents we previously filed with the SEC, many of which are beyond our control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein.*

### **Note Regarding Presentation of Non-GAAP Financial Measures**

*The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated October 27, 2014, to which the following supplemental slides are attached as Exhibit 99.2, provides further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with these supplemental slides.*

# Table of Contents

Q3 2014 Summary .....	4-7
Development .....	8
Quality .....	9
Revenues (Q3 2014 vs. Q3 2013) .....	10
Expenses (Q3 2014 vs. Q3 2013) .....	11
Adjusted EBITDA .....	12
Earnings per Share .....	13
Adjusted Free Cash Flow .....	14-15
2014 Guidance - Adjusted EBITDA .....	16
2014 Guidance - EPS.....	17
Income Tax Considerations.....	18
Adjusted Free Cash Flow Considerations .....	19
Priorities for Reinvesting Free Cash Flow .....	20
Appendix.....	21
Business Outlook: 2014 to 2016 .....	22
Our New-Store/Same-Store Growth .....	23
Debt Schedule and Maturity Profile .....	24-25
Revenues & Expenses (Sequential) .....	26
Revenues & Expenses (9 months) .....	27
Payment Sources (Percent of Revenues) .....	28
Operational and Labor Metrics .....	29-30
Outstanding Share Summary, Warrant Information and Conversion Price .....	31-32
Adjusted EBITDA History .....	33
Adjusted Free Cash Flow History.....	34
Reconciliations to GAAP .....	35-39

## Q3 2014 Summary (Q3 2014 vs. Q3 2013)

### ✓ Revenue growth of 5.8%

— Inpatient revenue growth of 6.6% (200 bps attributable to Fairlawn<sup>(1)</sup>)

- Discharge growth of 3.8% (compared to 5.7% in prior year)
  - Same-store discharge growth of 1.9% (negatively impacted by 40 bps for closure of 40 SNF beds)
  - New-store discharge growth of 1.9% (all attributable to Fairlawn<sup>(1)</sup>)
- Revenue per discharge increased by 2.7%, positively impacted by Medicare and managed care price adjustments.

### ✓ Outpatient and other revenues decline of 5.7% (\$2.0 million)

### ✓ Bad debt as a percent of revenue was 1.4%.

(1) HealthSouth acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased HealthSouth's ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method to a consolidated entity effective June 1, 2014.

## Q3 2014 Summary (Q3 2014 vs. Q3 2013) (cont.)

✓ **Salaries and benefits as a percent of revenue increased 80 bps mainly attributable to the following items:**

- Approx. \$3.3 million lower reduction in self-insurance reserves in Q3 2014 versus Q3 2013
  - Due to favorable trends in claims, the Company's reserves for group medical and workers' compensation were reduced by approx. \$3.0 million in Q3 2014 and approx. \$6.3 million in Q3 2013.
- Start-up costs for three de novos opening in Q4 2014

✓ **Hospital-related expenses as a percent of revenue were flat.**

- Occupancy expenses were approx. \$1.4 million lower resulting from the purchases of leased properties in 2013 and early 2014.
- Q3 2013 included an approx. \$1.5 million reduction in general and professional liability reserves due to favorable trends in claims.



(1) Hospital-related expenses include other operating expenses, supplies, and occupancy costs. Other operating expenses exclude the loss on disposal or impairment of assets.

(2) General & Administrative excludes stock-based compensation.

## Q3 2014 Summary (Q3 2014 vs. Q3 2013) (cont.)

- ✓ **Adjusted EBITDA<sup>(1)</sup> for the quarter of \$140.0 million increased by 3.3% impacted by:**
  - Approx. \$4.8 million in lower reductions to self-insurance reserves in Q3 2014 versus Q3 2013
  - Approx. \$2.0 million related to an additional equity interest in Fairlawn Rehabilitation Hospital
  - Approx. \$1.6 million for start-up costs at hospitals opening in Q4 2014
- ✓ **Diluted earnings<sup>(2)</sup> per share of \$0.53 reflected a lower tax rate (see table on slide 13)**
  - Q3 2014 income tax rate was reduced as a result of the nontaxable gain related to the acquisition of an additional 30% equity interest in Fairlawn Rehabilitation Hospital and the election to claim certain tax credits.
  - Q3 2013 diluted earnings per share of \$0.59 benefited from a \$21.3 million, or \$0.13 per diluted share, gain in government, class action and related settlements (recovery on judgments against former officers and related matters).
- ✓ **Adjusted free cash flow<sup>(3)</sup> for the quarter of \$103.3 million:**
  - Benefited from higher Adjusted EBITDA and lower dividends paid on perpetual preferred stock
  - Offset by growth in accounts receivable related to an increase in medical necessity claims denials primarily by one fiscal intermediary

(1) Reconciliation to GAAP provided on slides 35-39

(2) Income from continuing operations attributable to HealthSouth

(3) Reconciliation to GAAP provided on slide 34

## Q3 2014 Summary (cont.)

### ✓ **Balance sheet enhancements:**

- Amended credit facility to add a \$150 million term loan commitment to our existing \$600 million revolver and extend the maturity to 2019
- Issued an additional \$175 million of our existing 5.75% senior notes due 2024
- Redeemed all \$271 million of our 7.25% senior notes due 2018 (completed October 1, 2014)
- Provided notice (on October 24, 2014) to redeem 10% (~\$25 million) of our 7.75% senior notes due 2022 to be completed December 1, 2014

### ✓ **Shareholder distributions:**

- Paid quarterly cash dividend of \$0.18 per share on July 15, 2014
- Declared a \$0.21 per share (16.7% increase) quarterly dividend paid on October 15, 2014

# Development

## ✓ Continued construction of three de novos:


- Altamonte Springs, FL (50 beds); expect to open October 29, 2014
- Newnan, GA (50 beds); expect to open December 2014
- Middletown, DE (34 beds); expect to open December 2014

## ✓ New development:

- Continued progress towards owning and operating two new joint venture hospitals:
  - A 26-bed inpatient rehabilitation hospital in Johnson City, TN with Mountain States Health Alliance; expect to be operational by year-end 2014.
  - A 50-bed inpatient rehabilitation hospital in Savannah, GA with Memorial University Medical Center; expect to be operational in first half 2015.
- Received decision from the Tennessee Court of Appeals upholding order approving our plans to build a 40-bed inpatient rehabilitation hospital in Franklin, TN; expect to be operational in Q4 2015
- Continued the design and permitting process to construct a 50-bed inpatient rehabilitation hospital in Modesto, CA; expect to be operational in Q1 2016
- Acquired land and began the design and permitting process on a 50-bed inpatient rehabilitation hospital in Murrieta, CA; expect to be operational in Q4 2017

# Quality

✓ HealthSouth functional outcomes continue to outpace industry average<sup>(1)</sup>



**FIM® Gain** <sup>(2)</sup>  
FIM® is a tool for measuring functional independence. (FIM® Gain is based on the change from admission to discharge of an 18 point assessment.)

**LOS Efficiency**  
Functional gain divided by length of stay.

Source: UDSMR Database - On Demand Report: Q2 2014 Report

(1) Average = Expected, Risk-adjusted

(2) FIM® instrument is a trademark of Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc.

## Revenues (Q3 2014 vs. Q3 2013)

<i>(Millions)</i>	Q3 2014	Q3 2013	Increase/ (Decrease)
Inpatient	\$ 563.7	\$ 528.8	6.6%
Outpatient and other	33.2	35.2	(5.7%)
<b>Consolidated net operating</b>	<b>\$ 596.9</b>	<b>\$ 564.0</b>	<b>5.8%</b>
<i>(Actual Amounts)</i>			
Discharges	33,541	32,307	3.8%
Net patient revenue / discharge	\$ 16,806	\$ 16,368	2.7%

### ✓ Revenue growth of 5.8%

— Inpatient revenue growth of 6.6% (200 bps attributable to Fairlawn<sup>(1)</sup>)

- Discharge growth of 3.8% (compared to 5.7% in prior year)
  - Same-store discharge growth of 1.9% (negatively impacted by 40 bps for closure of 40 SNF beds)
  - New-store discharge growth of 1.9% (all attributable to Fairlawn<sup>(1)</sup>)
- Revenue per discharge increased by 2.7%, positively impacted by Medicare and managed care price adjustments.

### ✓ Outpatient and other revenues decline of 5.7% (\$2.0 million)

(1) HealthSouth acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased HealthSouth's ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method to a consolidated entity effective June 1, 2014.

## Expenses (Q3 2014 vs. Q3 2013)

<i>(Millions)</i>	Q3 2014	Q3 2013	Increase/ (Decrease)
<b>Salaries and benefits</b>	\$ 290.0	\$ 269.5	7.6%
Percent of net operating revenues	48.6%	47.8%	80 bps
EPOB (employees per occupied bed)	3.48	3.48	0.0%
<b>Hospital-related expenses</b>	\$ 123.6	\$ 116.9	5.7%
(other operating <sup>(1)</sup> , supplies, occupancy)			
Percent of net operating revenues	20.7%	20.7%	— bps
<b>General and administrative</b>	\$ 22.5	\$ 22.6	(0.4%)
(excludes stock-based compensation)			
Percent of net operating revenues	3.8%	4.0%	(20 bps)
<b>Provision for doubtful accounts</b>	\$ 8.2	\$ 8.0	2.5%
Percent of net operating revenues	1.4%	1.4%	— bps

✓ **Salaries and benefits as a percent of revenue increased 80 bps mainly attributable to the following items:**

- Approx. \$3.3 million lower reduction in self-insurance reserves in Q3 2014 versus Q3 2013
  - Due to favorable trends in claims, the Company's reserves for group medical and workers' compensation were reduced by approx. \$3.0 million in Q3 2014 and approx. \$6.3 million in Q3 2013.
- Start-up costs for three de novos opening in Q4 2014

✓ **Hospital-related expenses as a percent of revenue were flat.**

- Occupancy expenses were approx. \$1.4 million lower resulting from the purchases of leased properties in 2013 and early 2014.
- Q3 2013 included an approx. \$1.5 million reduction in general and professional liability reserves due to favorable trends in claims.

# Adjusted EBITDA <sup>(1)</sup>

(Millions)	Q3		9 Months	
	2014	2013	2014	2013
<b>Net operating revenues</b>	\$ 596.9	\$ 564.0	\$ 1,792.5	\$ 1,701.1
Less: Provision for doubtful accounts	(8.2)	(8.0)	(25.0)	(22.4)
Net operating revenues less provision for doubtful accounts	588.7	556.0	1,767.5	1,678.7
Operating expenses:				
Salaries and benefits	(290.0)	(269.5)	(861.4)	(817.7)
Hospital-related expenses:				
Other operating expenses <sup>(2)</sup>	(86.7)	(79.7)	(254.5)	(237.0)
Supplies	(26.6)	(25.5)	(82.0)	(78.3)
Occupancy costs	(10.3)	(11.7)	(31.1)	(35.8)
	(123.6)	(116.9)	(367.6)	(351.1)
General and administrative expenses <sup>(3)</sup>	(22.5)	(22.6)	(69.1)	(69.5)
Equity in nonconsolidated affiliates	1.9	2.0	8.8	8.2
Other income <sup>(4)</sup>	0.2	0.6	2.9	3.2
Noncontrolling interests	(14.7)	(14.1)	(44.3)	(42.5)
<b>Adjusted EBITDA</b>	<b>\$ 140.0</b>	<b>\$ 135.5</b>	<b>\$ 436.8</b>	<b>\$ 409.3</b>

(1) Reconciliation to GAAP provided on slides 35-39

	Q3		9 Months	
	2014	2013	2014	2013
In arriving at Adjusted EBITDA, the following were excluded:				
(2) Loss on disposal or impairment of assets	\$ 2.7	\$ 2.5	\$ 5.7	\$ 4.3
(3) Stock-based compensation expense	5.0	6.2	19.3	19.0
(4) Gain on consolidation of Fairlawn Rehabilitation Hospital	—	—	27.2	—

## Adjusted EBITDA Change

Q3 2014	9 Mos. 2014
+\$4.5M	+\$27.5M
+3.3%	+6.7%

### Q3 2014 was impacted by:

- Approx. \$4.8 million in lower reductions to self-insurance reserves in Q3 2014 versus Q3 2013
- Approx. \$2.0 million related to the additional equity interest in Fairlawn Rehabilitation Hospital
- Approx. \$1.6 million for start-up costs at hospitals opening in Q4 2014

### 9 Months 2014 was negatively impacted by:

- A net \$8 million for sequestration in Q1 2014

# Earnings per Share

(In Millions, Except Per Share Data)	Q3		9 Months	
	2014	2013	2014	2013
<b>Adjusted EBITDA</b>	\$ 140.0	\$ 135.5	\$ 436.8	\$ 409.3
Interest expense and amortization of debt discounts and fees	(27.8)	(25.3)	(83.5)	(73.9)
Depreciation and amortization	(27.4)	(24.3)	(80.2)	(69.5)
Stock-based compensation expense	(5.0)	(6.2)	(19.3)	(19.0)
Other, including noncash loss on disposal or impairment of assets	(2.7)	(2.5)	(5.7)	(4.3)
	<u>77.1</u>	<u>77.2</u>	<u>248.1</u>	<u>242.6</u>
<b>Certain nonrecurring items:</b>				
Government, class action, and related settlements	—	21.3	0.8	23.3
Gain on consolidation of Fairlawn Rehabilitation Hospital	—	—	27.2	—
Professional fees - accounting, tax, and legal	(4.0)	(4.2)	(7.6)	(7.8)
<b>Pre-tax income</b>	<u>73.1</u>	<u>94.3</u>	<u>268.5</u>	<u>258.1</u>
Income tax (expense) benefit <sup>(1)</sup>	(22.1) <sup>(2)</sup>	(35.2)	(91.4) <sup>(2)</sup>	17.8 <sup>(3)</sup>
<b>Income from continuing operations <sup>(4)</sup></b>	<u>\$ 51.0</u>	<u>\$ 59.1</u>	<u>\$ 177.1</u>	<u>\$ 275.9</u>
Income allocated to participating securities	(0.5)	(0.6)	(2.1)	(4.1)
Convertible perpetual preferred dividends	(1.6)	(5.7)	(4.7)	(17.2)
Interest and amortization on 2.0% Convertible Senior Subordinated Notes (net of tax) <sup>(5)</sup>	2.3	—	6.8	—
<b>Basic shares</b>	<u>86.5</u>	<u>86.2</u>	<u>86.8</u>	<u>88.7</u>
<b>Diluted shares</b>	<u>100.5</u>	<u>100.4</u>	<u>100.7</u>	<u>102.4</u>
<b>Basic earnings per share <sup>(4)</sup></b>	<u>\$ 0.56</u>	<u>\$ 0.61</u>	<u>\$ 1.96</u>	<u>\$ 2.87</u>
<b>Diluted earnings per share <sup>(4) (5)</sup></b>	<u>\$ 0.53</u>	<u>\$ 0.59</u>	<u>\$ 1.82</u>	<u>\$ 2.69</u>

## Q3 2014 reflects:

- Higher Adjusted EBITDA, interest expense and depreciation and amortization
- Lower certain nonrecurring items related to a \$21.3 million, or \$0.13 per diluted share, gain in government, class action and related settlements (recovery on judgments against former officers and related matters) in Q3 2013
- A lower tax rate <sup>(2)</sup>

(1) Current income tax expense was \$3.2 million, \$2.5 million, \$9.8 million, and \$3.0 million for Q3 2014, Q3 2013, 9 months 2014, and 9 months 2013, respectively.

(2) The Company's effective income tax rate was reduced as a result of the nontaxable gain related to its acquisition of an additional 30% equity interest in Fairlawn and the election to claim certain tax credits.

(3) Includes an approx. \$115 million (\$1.12 per diluted share share) benefit related to a settlement with the IRS

(4) Income from contributing operations attributable to HealthSouth

(5) The interest and amortization related to the convertible senior subordinated notes must be added to income from continuing operations when calculating diluted earnings per share.

# Adjusted Free Cash Flow <sup>(1)</sup>

(Millions)	Q3		9 Months	
	2014	2013	2014	2013
<b>Net cash provided by operating activities</b>	\$ 139.6	\$ 142.6	\$ 374.7	\$ 369.4
Impact of discontinued operations	(0.2)	1.2	1.0	1.4
<b>Net cash provided by operating activities of continuing operations</b>	139.4	143.8	375.7	370.8
Capital expenditures for maintenance <sup>(2)</sup>	(18.1)	(18.6)	(65.9)	(54.3)
Dividends paid on convertible perpetual preferred stock	(1.6)	(5.7)	(4.7)	(17.2)
Distributions paid to noncontrolling interests of consolidated affiliates	(14.2)	(10.2)	(39.6)	(34.1)
<b>Nonrecurring items:</b>				
Cash paid for professional fees - accounting, tax, and legal	4.1	1.7	7.3	5.3
Net premium on bond issuance/repayment	(6.3)	—	(6.3)	—
Cash received for government, class action, and related settlements	—	(4.6)	(0.6)	(5.9)
<b>Adjusted free cash flow <sup>(1)</sup></b>	<b>\$ 103.3</b>	<b>\$ 106.4</b>	<b>\$ 265.9</b>	<b>\$ 264.6</b>
<b>Cash dividends on common stock</b>	<b>\$ 15.8</b>	<b>\$ —</b>	<b>\$ 47.4</b>	<b>\$ —</b>


- ✓ **Adjusted free cash flow for the quarter of \$103.3 million:**
  - Benefited from higher Adjusted EBITDA and lower dividends paid on perpetual preferred stock
  - Offset by growth in accounts receivable related to an increase in medical necessity claims denials primarily by one fiscal intermediary

(1) Definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and nonrecurring items. Common stock dividends are not included in the calculation of adjusted free cash flow.

(2) Capital expenditures for maintenance are expected to be between \$85 million and \$95 million for 2014.

# Adjusted Free Cash Flow <sup>(1)</sup>

(Millions)	9 Months		Change	
	2014	2013	\$	%
Adjusted free cash flow <sup>(1)</sup>	\$265.9	\$264.6	1.3	0.5%



(1) Reconciliation to GAAP provided on slide 34.

(2) Working capital was impacted by higher payroll tax withholding related to the vesting of restricted stock awards in 2014 and growth in accounts receivable related to an increase in medical necessity claims denials primarily by one fiscal intermediary.

(3) Q1 2014 included approx. \$12 million for equipment purchases that were invoiced in Q4 2013 and paid in early 2014.

(4) On November 18, 2013, the Company closed separate, privately negotiated exchange agreements under which it issued \$320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's 6.5% Series A Convertible Perpetual Preferred Stock. The transaction will reduce preferred dividends by \$16.7 million in 2014.

## 2014 Guidance - Adjusted EBITDA<sup>(1)</sup>

**\$575 million to \$580 million**  
**(previous guidance**  
**\$570 million to \$580 million)**

### Considerations for October through December:

- ✓ **Revenue growth of 6.3% to 7.4%**
  - Discharge growth between 4.8% and 5.6%
  - Revenue per discharge growth between 2.3% and 2.6%
  - Lower outpatient revenues
- ✓ **Q4 2013 benefited from reductions to self-insurance reserves, including \$6.7 million attributable to lowering the Company's statistical confidence level.**
- ✓ **Includes the ramp up of three de novo hospitals expected to open in Q4 2014**
- ✓ **Bad debt expense of approx. 1.5%**

(1) Reconciliation to GAAP provided on slides 35, 38, and 39.

# 2014 Guidance - EPS

## Earnings per Share from Continuing Operations Attributable to HealthSouth <sup>(1)</sup>

**\$ 2.24 to \$ 2.27**

**(Previous guidance of \$2.25 to \$2.31 per share did not include the approx. \$0.08 per share loss on early extinguishment of debt )**

### Considerations:

- ✓ Includes \$13 million, or \$0.08 per share, loss on early extinguishment of debt in Q4 2014
- ✓ Higher depreciation and amortization related to recent capital investments
- ✓ Higher interest expense and amortization of debt discounts and fees related to the exchange of Convertible Senior Subordinated Notes for Convertible Perpetual Preferred Stock completed in Q4 2013
- ✓ Assumes provision for income tax of approx. 35% (cash taxes expected to be \$12 - \$17 million for full-year 2014)
- ✓ Share count is before the effect of any potential share repurchase activity

(1) Income from continuing operations attributable to HealthSouth

(2) The income allocated to participating securities, the convertible perpetual preferred dividends, and the repurchase premium on preferred stock need to be subtracted from income from continuing operations to calculate basic earnings per share.

(3) The interest and amortization related to the convertible senior subordinated notes must be added to income from continuing operations when calculating diluted earnings per share.

(4) Diluted earnings per share are the same as basic earnings per share due to antidilution.

	EPS Guidance		
	Actual	Low	High
	2013	2014	
<i>(In Millions, Except Per Share Data)</i>			
<b>Adjusted EBITDA</b>	<b>\$ 551.6</b>	<b>\$ 575</b>	<b>\$ 580</b>
Interest expense and amortization of debt discounts and fees	(100.4)	(110)	
Depreciation and amortization	(94.7)	(107)	
Stock-based compensation expense	(24.8)	(25)	
Other, including noncash loss on disposal and impairment of assets	(5.9)	(7)	
	325.8	326	331
<b>Certain Nonrecurring Expenses:</b>			
Government, class action, and related settlements	23.5	1	
Professional fees - accounting, tax, and legal	(9.5)	(8)	
Loss on early extinguishment of debt	(2.4)	(13)	
Gain related to consolidation of Fairlawn Rehabilitation Hospital	—	27	
	337.4	333	338
<b>Pre-tax income</b>	<b>337.4</b>	<b>333</b>	<b>338</b>
Income tax	(12.7)	(115)	(117)
	324.7	218	221
<b>Income from continuing operations <sup>(1)</sup></b>	<b>324.7</b>	<b>218</b>	<b>221</b>
Income allocated to participating securities <sup>(2)</sup>	(3.4)	(2)	(2)
Convertible perpetual preferred dividends <sup>(2)</sup>	(21.0)	(6)	(6)
Repurchase of convertible perpetual preferred stock <sup>(2)</sup>	(71.6)	—	—
After-tax convertible debt interest expense <sup>(3)</sup>	—	8	8
	88.1	87.0	87.0
Basic shares <sup>(2)</sup>	88.1	87.0	87.0
Diluted shares <sup>(3)</sup>	102.1	101.0	101.0
	2.59	2.24	2.27
<b>Earnings per share</b>	<b>\$ 2.59</b> <sup>(4)</sup>	<b>\$ 2.24</b>	<b>\$ 2.27</b>

# Income Tax Considerations

## GAAP Considerations:

- As of 9/30/14, the Company's federal NOL had a gross balance of approx. \$688 million.
- The Company has a remaining valuation allowance of approx. \$30 million related to state NOLs.

## Cash Tax Payment:

- In 2014, the Company expects to pay approx. \$12 million to \$17 million of income tax, net of refunds.
- HealthSouth is not currently subject to an annual use limitation ("AUL") under Internal Revenue Code Section 382 ("Section 382"). An "ownership change," as defined by Section 382, could subject the Company to an AUL, which would approximate the value of the Company at the time of the "ownership change" multiplied by the long-term tax exempt rate.

# Adjusted Free Cash Flow <sup>(1)</sup> Considerations

Adjusted free cash flow for 2014 is expected to increase over 2013.

Certain Cash Flow Items <sup>(2)</sup> (millions)	2013 Actual	9 months 2014 Actual	2014 Assumptions
• Cash interest expense <sup>(3)</sup>	\$95.4	\$74.1	\$97
• Cash payments for taxes, net of refunds	\$7.7	\$14.8	\$12 to \$17
• Working Capital and Other	\$19.6	\$11.4	\$30 to \$40
• Maintenance CAPEX <sup>(4)</sup>	\$74.8	\$65.9	\$85 to \$95
• Dividends paid on preferred stock	\$23.0	\$4.7	\$6

## Adjusted Free Cash Flow <sup>(1)</sup>



(1) Reconciliation to GAAP is provided on slide 34.

(2) Definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and nonrecurring items. Common stock dividends (approx. \$16 million paid in Q4 2013 and approx. \$66 million paid in 2014) are not included in the calculation of adjusted free cash flow.

(3) Net of amortization of debt discounts and fees

(4) 2013 benefited by approx. \$12 million for equipment purchases that were invoiced in Q4 2013 and paid in early 2014.

# Priorities for Reinvesting Free Cash Flow

		(millions)			
		2013 Actuals	9 Months Actuals	2014 Assumptions	
	<b>Growth in Core Business</b>	Bed expansions (target~ 80 beds/yr) and unit consolidations	\$24.9	\$16.4	\$25 to \$35
		New IRF's (target 4-6/yr)	55.5	44.9	55 to 75
		Fairlawn transaction	—	15.9	—
			\$80.4	\$77.2	\$80 to \$110, excluding acquisitions
<b>Objectives Achieved</b>	<b>Debt Reduction</b>	Pro forma debt pay down, net <sup>(1)(2)</sup>	(\$264.0)	\$64.9	N/A
		Purchase leased properties	90.3	19.5	20
<b>Complements Growth Investments</b>	<b>Shareholder Distributions</b>	Convertible preferred stock repurchase <sup>(1)</sup>	249.0	—	—
		Cash dividends on common stock <sup>(3)</sup>	15.7	47.4	66
		Common stock repurchase (~\$207 million authorization remaining as of September 30, 2014) <sup>(4)</sup>	234.1	43.1	TBD
			\$325.1	\$174.9	TBD

(1) Issued \$320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's 6.5% Series A Convertible Perpetual Preferred Stock. Excluding fees, no cash was used in the transaction. The Company recorded approx. \$249 million as debt and approx. \$71 million as equity.

(2) Issued an additional \$175 million of existing 5.75% senior notes due 2024 and redeemed all \$271 million of 7.25% senior notes due 2018 (slide 24)

(3) On July 25, 2013, the board of directors approved the initiation of a quarterly cash dividend on our common stock of \$0.18 per share. On July 17, 2014, the board of directors approved a \$0.03 per share, or 16.7%, increase to the quarterly cash dividend on our common stock.

(4) On February 14, 2014, the board of directors approved an increase in our existing common stock repurchase authorization from \$200 million to \$250 million. The \$234 million reflects the tender offer completed in Q1 2013 for approx. 9.5% of the common shares.

# Appendix

# Business Outlook: 2014 to 2016<sup>(1)</sup>

## Business Model

- Adjusted EBITDA CAGR: 4-8% <sup>(2)</sup>
- Continued strong free cash flow generation

Potential depletion of the federal NOL during the 2014 to 2016 timeframe will affect Cash Flow CAGR.


Strategy	2013	2014	2015	2016
<b>Shareholder Distributions</b>	\$234 million common stock tender; initiated dividends	<ul style="list-style-type: none"> <li>• Quarterly cash dividends (increased from \$0.18 to \$0.21 per common share)</li> <li>• Opportunistic share repurchases (\$43.1 million; 1.3 million common shares repurchased in the first 9 months of 2014)</li> </ul>		
<b>Leverage</b>	< 3.0x Debt to Adjusted EBITDA	< 3.0x Debt to Adjusted EBITDA (subject to shareholder value-creating opportunities)		
<b>Core Growth</b>	<b>Bed expansion = 68</b>	<b>Same-store Growth</b> (Includes bed expansions and unit consolidations)		
	<b>New IRF's = 3</b> Littleton, CO, Stuart, FL, Augusta, GA	<b>New IRF's</b> (target of 4-6/year) Altamonte Springs, FL; Newnan, GA; Middletown, DE; Johnson City TN	<b>New IRF's</b> (target of 4-6/year)	
<b>Opportunistic Growth</b>		Consider disciplined acquisitions		
<b>Key Operational Initiatives</b>	• <b>Enhancing outcomes and patient experience</b>			
	• <b>Implementing CIS:</b> Target 20 hospitals/year; Installation complete in 56 hospitals; Expect installation at all hospitals by YE2017.			
	• <b>Positioning for evolving delivery and payment models:</b> ACO, bundling, IMPACT Act, etc.			

(1) If legislation affecting Medicare is passed, HealthSouth will evaluate its effect on the Company's business model.

(2) This is a multi-year CAGR; annual results may fall outside the range. Reconciliation to GAAP provided on slides 35-39.

# Our New-Store/Same-Store Growth

HealthSouth's volume growth is driven by bed expansions and new IRFs



- (1) HealthSouth acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased HealthSouth's ownership interest from 50% to 80% and resulted in a change in accounting for the hospital from the equity method to a consolidated entity effective June 1, 2014.
- (2) In Q3 2012, HealthSouth amended the joint venture agreement related to St. Vincent Rehabilitation Hospital in Sherwood, AR which resulted in a change in accounting for this hospital from the equity method of accounting to a consolidated entity. Moved to same store in Q3 2013.

# Debt Schedule

(Millions)	Corporate	Credit Rating		Pro Forma Post Issuance and Redemption <sup>(1)</sup>	Sept. 30, 2014	Dec. 31, 2013	Pro Forma Change in Debt vs. YE 2013
		S&P BB-	Moody Ba3				
Advances under \$600 million revolving credit facility, September 2019 - 1 Month LIBOR +175bps <sup>(1)</sup>		BB+	Baa3	\$ —	\$ —	\$ 45.0	\$ (45.0)
Term loan facility, September 2019 - 1 Month LIBOR +175bps <sup>(1)</sup>		BB+	Baa3	75.0	—	—	75.0
Bonds Payable:							
7.25% Senior Notes due 2018 <sup>(1)</sup>		BB-	Ba3	—	272.3	272.4	(272.4)
8.125% Senior Notes due 2020		BB-	Ba3	286.9	286.9	286.6	0.3
7.75% Senior Notes due 2022		BB-	Ba3	252.4	252.4	252.5	(0.1)
5.75% Senior Notes due 2024 <sup>(1)</sup>		BB-	Ba3	456.3	456.3	275.0	181.3
2.00% Convertible Senior Subordinated Notes due 2043 <sup>(2)</sup>				255.8	255.8	249.5	6.3
Other notes payable				41.9	41.9	47.6	(5.7)
Capital lease obligations				84.3	84.3	88.9	(4.6)
<b>Long-term debt</b>				<b>\$ 1,452.6</b>	<b>\$ 1,649.9</b>	<b>\$ 1,517.5</b>	<b>\$ (64.9)</b>
<b>Debt to Adjusted EBITDA <sup>(3)</sup></b>				<b>2.5x</b>	<b>2.8x</b>	<b>2.8x</b>	

(1) In September 2014, the Company issued an additional \$175 million of its 5.75% senior notes due 2024 and amended the credit agreement governing its senior secured credit facility to extend the maturity to September 2019 and add a \$150 million term loan commitment. In October 2014, the Company redeemed all of its 7.25% senior notes due 2018.

(2) On November 18, 2013, the Company closed separate, privately negotiated exchange agreements under which it issued \$320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's 6.5% Series A Convertible Perpetual Preferred Stock. The Company recorded approx. \$249 million as debt and approx. \$71 million as equity.


(3) Based on 4 Qtr. trailing and 2013 Adjusted EBITDA of \$579.1 million and \$551.6 million, respectively; reconciliation to GAAP provided on slides 35-39

# Debt Maturity Profile

HealthSouth is positioned with a cost-efficient, flexible capital structure..

## Pro forma September 30, 2014 <sup>(1) (2)</sup> for Issuance, Redemption and Credit Facility Amendment

(\$ in millions)



- (1) Does not include approx. \$93 million of convertible perpetual preferred stock, approx. \$84 million of capital leases, and approx. \$42 million of other notes payable.
- (2) In September 2014, the Company issued an additional \$175 million of its 5.75% senior notes due 2024 and amended the credit agreement governing its senior secure credit facility to extend the maturity to September 2019 and add a \$150 million term loan commitment. In October 2014, the Company redeemed all of its 7.25% senior notes due 2018.
- (3) The 2022 and 2024 Senior Notes become callable in 2015 and 2017, respectively.
- (4) On November 18, 2013, the Company closed separate, privately negotiated exchange agreements under which it issued \$320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's 6.5% Series A Convertible Perpetual Preferred Stock. The Company recorded approx. \$249 million as debt and approx. \$71 million as equity. As of 9/30/14, approx. \$64 million remains as an unamortized debt discount.

# Revenues & Expenses (Sequential)

	Q3 2014	Q2 2014	Increase/ (Decrease)
<b>Revenues (millions)</b>			
<b>Inpatient</b>	\$ 563.7	\$ 569.7	(1.1%)
<b>Outpatient and other</b>	33.2	34.7	(4.3%)
<b>Consolidated net operating</b>	<u>\$ 596.9</u>	<u>\$ 604.4</u>	<u>(1.2%)</u>
(Actual Amounts)			
Discharges	33,541	33,620	(0.2%)
Net patient revenue / discharge	\$ 16,806	\$ 16,945	(0.8%)
<b>Expenses (millions)</b>			
<b>Salaries and benefits</b>	\$ 290.0	\$ 285.3	1.6%
Percent of net operating revenues	48.6%	47.2%	140 bps
EPOB (employees per occupied bed)	3.48	3.39	2.7%
<b>Hospital-related expenses</b>	\$ 123.6	\$ 122.7	0.7%
(other operating <sup>(1)</sup> , supplies, occupancy)			
Percent of net operating revenues	20.7%	20.3%	40 bps
<b>General and administrative</b>	\$ 22.5	\$ 23.2	(3.0%)
(excludes stock-based compensation)			
Percent of net operating revenues	3.8%	3.8%	— bps
<b>Provision for doubtful accounts</b>	\$ 8.2	\$ 9.3	(11.8%)
Percent of net operating revenues	1.4%	1.5%	(10 bps)

(1) Excludes loss on disposal or impairment of assets

## Revenues & Expenses (9 months)

	<b>9 Months 2014</b>	<b>9 Months 2013</b>	<b>Increase/ (Decrease)</b>
<b>Revenues (millions)</b>			
<b>Inpatient</b>	\$ 1,691.6	\$ 1,593.3	6.2%
<b>Outpatient and other</b>	100.9	107.8	(6.4%)
<b>Consolidated net operating</b>	<u>\$ 1,792.5</u>	<u>\$ 1,701.1</u>	<u>5.4%</u>
(Actual Amounts)			
Discharges	100,050	97,082	3.1%
Net patient revenue / discharge	\$ 16,908	\$ 16,412	3.0%
<b>Expenses (millions)</b>			
<b>Salaries and benefits</b>	\$ 861.4	\$ 817.7	5.3%
Percent of net operating revenues	48.1%	48.1%	— bps
EPOB (employees per occupied bed)	3.40	3.40	—%
<b>Hospital-related expenses</b>	\$ 367.6	\$ 351.1	4.7%
(other operating <sup>(1)</sup> , supplies, occupancy)			
Percent of net operating revenues	20.5%	20.6%	(10 bps)
<b>General and administrative</b>	\$ 69.1	\$ 69.5	(0.6%)
(excludes stock-based compensation)			
Percent of net operating revenues	3.9%	4.1%	(20 bps)
<b>Provision for doubtful accounts</b>	\$ 25.0	\$ 22.4	11.6%
Percent of net operating revenues	1.4%	1.3%	10 bps

(1) Excludes loss on disposal or impairment of assets

## Payment Sources (Percent of Revenues)

	Q3		9 Months		Full Year	
	2014	2013	2014	2013	2013	2012
Medicare	73.5%	74.1%	74.1%	74.5%	74.5%	73.4%
Medicaid	2.2%	1.5%	1.8%	1.2%	1.2%	1.2%
Workers' compensation	1.1%	1.3%	1.2%	1.3%	1.2%	1.5%
Managed care and other discount plans, including Medicare Advantage <sup>(1)</sup>	18.8%	18.7%	18.6%	18.5%	18.5%	19.3%
Other third-party payors	1.8%	1.7%	1.7%	1.7%	1.8%	1.8%
Patients	1.1%	1.1%	1.0%	1.1%	1.1%	1.3%
Other income	1.5%	1.6%	1.6%	1.7%	1.7%	1.5%
<b>Total</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>	<b>100.0%</b>

(1) Medicare Advantage revenues represent ~ 7% of total revenue for Q3 2013 and 8% of total revenues for all other periods presented.

# Operational and Labor Metrics

	Q3 2014	Q2 2014	Q1 2014	Q4 2013	Q3 2013	Q2 2013	Q1 2013	Q4 2012	Q3 2012	Q2 2012	Q1 2012	Full Year	
												2013	2012
(In Millions)													
Net patient revenue-inpatient	\$ 563.7	\$ 569.7	\$ 558.2	\$ 537.5	\$ 528.8	\$ 527.4	\$ 537.1	\$ 518.1	\$ 498.9	\$ 495.0	\$ 500.6	\$ 2,130.8	\$ 2,012.6
Net patient revenue-outpatient and other revenues	33.2	34.7	33.0	34.6	35.2	37.1	35.5	34.8	38.1	38.4	38.0	142.4	149.3
Net operating revenues	\$ 596.9	\$ 604.4	\$ 591.2	\$ 572.1	\$ 564.0	\$ 564.5	\$ 572.6	\$ 552.9	\$ 537.0	\$ 533.4	\$ 538.6	\$ 2,273.2	\$ 2,161.9
(Actual Amounts)													
Discharges <sup>(1)</sup>	33,541	33,620	32,889	32,906	32,307	32,645	32,130	31,695	30,569	30,719	30,871	129,988	123,854
Outpatient visits	183,450	189,540	182,170	192,474	202,479	211,207	200,471	198,139	221,648	229,152	231,243	806,631	880,182
Average length of stay	13.2	13.1	13.4	13.1	13.3	13.2	13.5	13.2	13.6	13.4	13.5	13.3	13.4
Occupancy %	69.6%	70.5%	71.9%	68.6%	69.0%	69.9%	72.4%	68.2%	68.3%	69.2%	70.7%	69.3%	68.2%
# of licensed beds	6,890	6,884	6,825	6,825	6,789	6,777	6,646	6,656	6,598	6,538	6,500	6,825	6,656
Occupied beds	4,795	4,853	4,907	4,682	4,684	4,737	4,812	4,539	4,506	4,524	4,596	4,730	4,539
Full-time equivalents (FTEs) <sup>(2)</sup>	16,614	16,374	16,209	16,159	16,213	16,180	15,819	15,617	15,545	15,378	15,271	16,093	15,453
Contract labor	77	99	83	72	76	72	85	73	61	56	69	76	65
Total FTE and contract labor	16,691	16,473	16,292	16,231	16,289	16,252	15,904	15,690	15,606	15,434	15,340	16,169	15,518
EPOB <sup>(3)</sup>	3.48	3.39	3.32	3.47	3.48	3.43	3.31	3.46	3.46	3.41	3.34	3.42	3.42

(1) Represents discharges from HealthSouth's 102 consolidated hospitals in Q3 2014 and Q2 2014; 101 consolidated hospitals in Q1 2014, Q4 2013, Q3 2013 and Q2 2013; 98 consolidated hospitals in Q1 2013 and Q4 2012; 97 consolidated hospitals in Q3 2012; 96 consolidated hospitals in Q2 2012 and Q1 2012.

(2) Excludes approximately 400 full-time equivalents who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company's consolidated statements of operations. Full-time equivalents included in the above table represent HealthSouth employees who participate in or support the operations of the Company's hospitals.

(3) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.

# Operational and Labor Metrics Impact of Fairlawn Rehabilitation Hospital Consolidation

	Fairlawn Rehabilitation Hospital as Consolidated Entity <sup>(1)</sup>	Fairlawn Rehabilitation Hospital as Equity Method Entity <sup>(1)</sup>		Fairlawn Rehabilitation Hospital as Consolidated Entity <sup>(1)</sup>	Fairlawn Rehabilitation Hospital as Equity Method Entity <sup>(1)</sup>	
	Q3 2014 As Reported	Q3 2014 Without Accounting or Ownership Change	Difference	9 Months 2014 As Reported	9 Months 2014 Without Accounting or Ownership Change	Difference
(In Millions)						
Net patient revenue-inpatient	\$ 563.7	\$ 553.0	\$ 10.7	\$ 1,691.6	\$ 1,676.6	\$ 15.0
Net patient revenue-outpatient and other revenues	33.2	33.6	(0.4)	100.9	101.3	(0.4)
Net operating revenues	<u>\$ 596.9</u>	<u>\$ 586.6</u>	<u>\$ 10.3</u>	<u>\$ 1,792.5</u>	<u>\$ 1,777.9</u>	<u>\$ 14.6</u>
Actual Amounts						
Discharges	33,541	32,910	631	100,050	99,210	840
Outpatient visits	183,450	180,852	2,598	555,160	551,713	3,447
Average length of stay (days)	13.2	13.2	—	13.2	13.2	—
Occupancy %	69.6%	69.5%	0.1%	70.4%	71.0%	(0.6%)
# of licensed beds	6,890	6,780	110	6,890	6,780	110
Occupied beds	4,795	4,712	83	4,851	4,814	37
Full-time equivalents (FTEs) <sup>(2)</sup>	16,614	16,330	284	16,399	16,272	127
Contract labor	77	—	77	86	—	86
Total FTE and contract labor	<u>16,691</u>	<u>16,330</u>	<u>361</u>	<u>16,485</u>	<u>16,272</u>	<u>213</u>
EPOB <sup>(3)</sup>	3.48	3.48	—	3.40	3.40	—

(1) HealthSouth acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased HealthSouth's ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method to a consolidated entity effective June 1, 2014.

(2) (3) - Notes on page 29

# Outstanding Share Summary, Warrant Information, and Conversion Price

(Millions)	Weighted Average for the Period						
	Q3		9 months		Full Year		
	2014	2013	2014	2013	2013	2012	2011
<b>Basic shares outstanding</b> <sup>(1) (2) (3)</sup>	86.5	86.2	86.8	88.7	88.1	94.6	93.3
<b>Diluted shares outstanding</b> <sup>(1) (2) (3) (4)</sup>	100.5	100.4	100.7	102.4	102.1	108.1	109.2

(Millions)	End of Period						
	Q3		9 months		Full Year		
	2014	2013	2014	2013	2013	2012	2011
<b>Basic shares outstanding</b> <sup>(1) (2) (3)</sup>	86.5	86.3	86.5	86.3	86.8	94.6	93.3
<b>Convertible perpetual preferred stock</b> <sup>(4)</sup>	0.096	0.353	0.096	0.353	0.096	0.353	0.400
<b>If converted, equivalent common shares</b>	3.2	11.6	3.2	11.6	3.2	11.6	13.1
<b>Convertible senior subordinated notes</b> <sup>(4)</sup>	\$320.0	—	\$320.0	—	\$320.0	—	—
<b>If converted, equivalent common shares</b>	8.2	—	8.1	—	8.1	—	—

	Date	Approx. Conversion Rates	Approx. Conversion Price
<b>Convertible perpetual preferred stock</b>	10/2/2014	33.6700	\$29.70
<b>Convertible senior subordinated notes</b>	10/2/2014	25.7582	\$38.82

(1) (2) (3) (4) – Notes on page 32

# Outstanding Share Summary, Warrant Information, and Conversion Price Notes

- (1) The Company purchased 9,119,450 common shares in Q1 2013 through a tender offer at a price of \$25.50 per share.
- (2) 10 million warrants (pre-October 2006 reverse split) were issued in connection with a January 2004 loan repaid to Credit Suisse First Boston. The warrants expired on January 16, 2014. The holders of these warrants chose both cash and cashless exercises into shares of our common stock. Prior to warrant expiration, 755,323 shares of our common stock were issued upon exercise between September 30, 2013 and January 16, 2014.
- (3) The agreement to settle our class action securities litigation received final court approval in January 2007. These shares of common stock and warrants were issued on September 30, 2009. The 5.0 million of common shares are included in the outstanding shares. The warrants to purchase approx. 8.2 million shares of common stock at a strike price of \$41.40 (expire January 17, 2017) were not assumed exercised for the dilutive shares outstanding because they were antidilutive in the periods presented.
- (4) The difference between the basic and diluted shares outstanding is primarily related to the convertible senior subordinated notes and our convertible perpetual preferred stock (convertible into 8.2 million and 3.2 million common shares, respectively, as of September 30, 2014).
  - a. On November 18, 2013, the Company closed separate, privately negotiated exchanges in which it issued \$320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's 6.5% Series A Convertible Perpetual Preferred Stock. The Company recorded approx. \$249 million as debt and approx. \$71 million as equity. The convertible notes are convertible, at the option of the holders, at any time on or prior to the close of business on the business day immediately preceding December 1, 2043 into shares of the Company's common stock at a conversion rate of approx. 25.7582 shares per \$1,000 in principal amount, which is equal to a conversion price of approximately \$38.82 per share, subject to customary antidilution adjustments. The Company has the right to redeem the convertible notes before December 1, 2018 if the volume weighted average price of the Company's common stock is at least 120% (\$46.58) of the conversion price of the convertible notes for a specified period. On or after December 1, 2018, the Company may, at its option, redeem all or any part of the convertible notes. In either case, the redemption price will be equal to 100% of the principal amount of the convertible notes to be redeemed, plus accrued and unpaid interest. As a result of the transaction, the dividend on the convertible perpetual preferred stock was reduced from approx. \$5.7 million per quarter to approx. \$1.6 million per quarter.
  - b. The 96,245 shares of preferred stock outstanding after the exchange transaction are convertible at the option of the holder, at any time into shares of common stock at a conversion price of \$29.70 per share, which is equal to a conversion rate of approx. 33.6700 shares of common stock per share of preferred stock, subject to a specified adjustment. We may at any time cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% (\$44.55) of the conversion price of the preferred stock.

# Adjusted EBITDA History <sup>(1)</sup>

(Millions)	Q3 2014	Q2 2014	Q1 2014	Q4 2013	Q3 2013	Q2 2013	Q1 2013	9 Months 2014	9 Months 2013	Full Year 2013	Full Year 2012
<b>Net operating revenues</b>	\$ 596.9	\$ 604.4	\$ 591.2	\$ 572.1	\$ 564.0	\$ 564.5	\$ 572.6	\$1,792.5	\$1,701.1	\$2,273.2	\$2,161.9
Less: Provision for doubtful accounts	(8.2)	(9.3)	(7.5)	(3.6)	(8.0)	(7.0)	(7.4)	(25.0)	(22.4)	(26.0)	(27.0)
Net operating revenues less provision for doubtful accounts	588.7	595.1	583.7	568.5	556.0	557.5	565.2	1,767.5	1,678.7	2,247.2	2,134.9
Operating expenses:											
Salaries and benefits	(290.0)	(285.3)	(286.1)	(272.0)	(269.5)	(273.6)	(274.6)	(861.4)	(817.7)	(1,089.7)	(1,050.2)
Hospital-related expenses:											
Other operating expenses <sup>(2)</sup>	(86.7)	(84.6)	(83.2)	(80.1)	(79.7)	(79.3)	(78.0)	(254.5)	(237.0)	(317.1)	(299.4)
Supplies	(26.6)	(27.8)	(27.6)	(27.1)	(25.5)	(26.6)	(26.2)	(82.0)	(78.3)	(105.4)	(102.4)
Occupancy costs	(10.3)	(10.3)	(10.5)	(11.2)	(11.7)	(11.9)	(12.2)	(31.1)	(35.8)	(47.0)	(48.6)
	(123.6)	(122.7)	(121.3)	(118.4)	(116.9)	(117.8)	(116.4)	(367.6)	(351.1)	(469.5)	(450.4)
General/Administrative expenses <sup>(3)</sup>	(22.5)	(23.2)	(23.4)	(24.8)	(22.6)	(23.0)	(23.9)	(69.1)	(69.5)	(94.3)	(93.8)
Equity in nonconsolidated affiliates	1.9	2.6	4.3	3.0	2.0	3.3	2.9	8.8	8.2	11.2	12.7
Other income <sup>(4)(5)</sup>	0.2	1.0	1.7	1.3	0.6	1.9	0.7	2.9	3.2	4.5	3.6
Noncontrolling interests	(14.7)	(14.8)	(14.8)	(15.3)	(14.1)	(13.8)	(14.6)	(44.3)	(42.5)	(57.8)	(50.9)
<b>Adjusted EBITDA</b>	<b>\$ 140.0</b>	<b>\$ 152.7</b>	<b>\$ 144.1</b>	<b>\$ 142.3</b>	<b>\$ 135.5</b>	<b>\$ 134.5</b>	<b>\$ 139.3</b>	<b>\$ 436.8</b>	<b>\$ 409.3</b>	<b>\$ 551.6</b>	<b>\$ 505.9</b>

(1) Reconciliation to GAAP provided on slides 35-39

	Q3 2014	Q2 2014	Q1 2014	Q4 2013	Q3 2013	Q2 2013	Q1 2013	9 Months 2014	9 Months 2013	Full Year 2013	Full Year 2012
In arriving at Adjusted EBITDA, the following were excluded:											
(2) Loss on disposal or impairment of assets	\$ 2.7	\$ 1.7	\$ 1.3	\$ 1.6	\$ 2.5	\$ 1.7	\$ 0.1	\$ 5.7	\$ 4.3	\$ 5.9	\$ 4.4
(3) Stock-based compensation expense	5.0	7.0	7.3	5.8	6.2	6.5	6.3	19.3	19.0	24.8	24.1
(4) Gain on consolidation of St. Vincent Rehabilitation Hospital	—	—	—	—	—	—	—	—	—	—	4.9
(5) Gain on consolidation of Fairlawn Rehabilitation Hospital	—	27.2	—	—	—	—	—	27.2	—	—	—

# Adjusted Free Cash Flow <sup>(1)</sup> History

(Millions)	Q3		9 Months		Full Year		
	2014	2013	2014	2013	2013	2012	2011
<b>Net cash provided by operating activities</b>	\$ 139.6	\$ 142.6	\$ 374.7	\$ 369.4	\$ 470.3	\$ 411.5	\$ 342.7
Impact of discontinued operations	(0.2)	1.2	1.0	1.4	1.9	(2.0)	(9.1)
<b>Net cash provided by operating activities of continuing operations</b>	139.4	143.8	375.7	370.8	472.2	409.5	333.6
Capital expenditures for maintenance <sup>(2)</sup>	(18.1)	(18.6)	(65.9)	(54.3)	(74.8)	(83.0)	(50.8)
Net settlements on interest rate swaps	—	—	—	—	—	—	(10.9)
Dividends paid on convertible perpetual preferred stock	(1.6)	(5.7)	(4.7)	(17.2)	(23.0)	(24.6)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(14.2)	(10.2)	(39.6)	(34.1)	(46.3)	(49.3)	(44.2)
<b>Non-recurring items:</b>							
Net premium (received) paid on bond issuance/redemption	(6.3)	—	(6.3)	—	1.7	1.9	22.8
Cash paid for professional fees - accounting, tax, and legal	4.1	1.7	7.3	5.3	7.0	16.1	21.0
Cash paid for government, class action, and related settlements	—	(4.6)	(0.6)	(5.9)	(5.9)	(2.6)	5.7
Income tax refunds related to prior periods	—	—	—	—	—	—	(7.9)
<b>Adjusted free cash flow <sup>(1)</sup></b>	<b>\$ 103.3</b>	<b>\$ 106.4</b>	<b>\$ 265.9</b>	<b>\$ 264.6</b>	<b>\$ 330.9</b>	<b>\$ 268.0</b>	<b>\$ 243.3</b>
<b>Cash dividends on common stock</b>	<b>\$ 15.8</b>	<b>—</b>	<b>\$ 47.4</b>	<b>—</b>	<b>\$ 15.7</b>	<b>—</b>	<b>—</b>

(1) Definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and nonrecurring items. Common stock dividends are not included in the calculation of adjusted free cash flow.

(2) Capital expenditures for maintenance are expected to be between \$85 million and \$95 for 2014.

# Reconciliation of Net Income to Adjusted EBITDA <sup>(1)</sup>

(in millions, except per share data)	2014							
	Q1		Q2		Q3		9 Months	
	Total	Per Share						
<b>Net Income</b>	\$ 61.5		\$ 97.9		\$ 64.8		\$ 224.2	
Loss (income) from disc ops, net of tax, attributable to HealthSouth	0.1		(3.8)		0.9		(2.8)	
Net income attributable to noncontrolling interests	(14.8)		(14.8)		(14.7)		(44.3)	
<b>Income from continuing operations attributable to HealthSouth <sup>(2)</sup></b>	46.8	\$ 0.48	79.3	\$ 0.81	51.0	\$ 0.53	177.1	\$ 1.82
Gov't, class action, and related settlements	—		(0.8)		—		(0.8)	
Pro fees - acct, tax, and legal	1.6		2.0		4.0		7.6	
Provision for income tax expense	32.8		36.5		22.1		91.4	
Interest expense and amortization of debt discounts	27.9		27.8		27.8		83.5	
Depreciation and amortization	26.4		26.4		27.4		80.2	
Gain on consolidation of Fairlawn Rehabilitation Hospital	—		(27.2)		—		(27.2)	
Other, including net noncash loss on disposal or impairment of assets	1.3		1.7		2.7		5.7	
Stock-based compensation expense	7.3		7.0		5.0		19.3	
<b>Adjusted EBITDA <sup>(1)</sup></b>	<u>\$ 144.1</u>		<u>\$ 152.7</u>		<u>\$ 140.0</u>		<u>\$ 436.8</u>	
<b>Weighted average common shares outstanding:</b>								
Basic		<u>87.3</u>		<u>86.7</u>		<u>86.5</u>		<u>86.8</u>
Diluted		<u>100.9</u>		<u>100.6</u>		<u>100.5</u>		<u>100.7</u>

(1) (2) - See notes on slide 38

# Reconciliation of Net Income to Adjusted EBITDA <sup>(1)</sup> - Impact of Consolidation of Fairlawn Rehabilitation Hospital <sup>(3)</sup>

	Fairlawn Rehabilitation Hospital as Consolidated Entity <sup>(3)</sup>		Fairlawn Rehabilitation Hospital as Equity Method Entity <sup>(3)</sup>		Difference		Fairlawn Rehabilitation Hospital as Consolidated Entity <sup>(3)</sup>		Fairlawn Rehabilitation Hospital as Equity Method Entity <sup>(3)</sup>		Difference	
	Q3 2014 As Reported		Q3 2014 Without Accounting or Ownership Change				9 Months 2014 As Reported		9 Months 2014 Without Accounting or Ownership Change			
	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share	Total	Per Share
<b>Net income</b>	\$ 64.8		\$ 61.6		\$ 3.2		\$ 224.2		\$ 195.1		\$ 29.1	
Income from discops, net of tax, attributable to HealthSouth	0.9		0.9		—		(2.8)		(2.8)		—	
Net income attributable to noncontrolling interests	(14.7)		(14.4)		(0.3)		(44.3)		(43.7)		(0.6)	
<b>Income from continuing operations attributable to HealthSouth <sup>(2)</sup></b>	<u>51.0</u>	<u>\$ 0.53</u>	<u>48.1</u>	<u>\$ 0.50</u>	<u>2.9</u>	<u>\$ 0.03</u>	<u>177.1</u>	<u>\$ 1.82</u>	<u>148.6</u>	<u>\$ 1.54</u>	<u>28.5</u>	<u>\$ 0.28</u>
Gov't, class action, and related settlements	—		—		—		(0.8)		(0.8)		—	
Pro fees-acct, tax, and legal	4.0		4.0		—		7.6		7.6		—	
Provision for income tax expense	22.1		23.6		(1.5)		91.4		90.4		1.0	
Interest expense and amortization of debt discounts and fees	27.8		27.8		—		83.5		83.5		—	
Depreciation and amortization	27.4		26.7		0.7		80.2		79.2		1.0	
Gain on consolidation of Fairlawn Rehabilitation Hospital	—		—		—		(27.2)		—		(27.2)	
Other, including net noncash loss on disposal or impairment of assets	2.7		2.8		(0.1)		5.7		5.7		—	
Stock-based compensation expense	5.0		5.0		—		19.3		19.3		—	
<b>Adjusted EBITDA <sup>(1)</sup></b>	<u>\$ 140.0</u>		<u>\$ 138.0</u>		<u>\$ 2.0</u>		<u>\$ 436.8</u>		<u>\$ 433.5</u>		<u>\$ 3.3</u>	
<b>Weighted average common shares outstanding:</b>												
Basic		<u>86.5</u>		<u>86.5</u>		<u>—</u>		<u>86.8</u>		<u>86.8</u>		<u>—</u>
Diluted		<u>100.5</u>		<u>100.5</u>		<u>—</u>		<u>100.7</u>		<u>100.7</u>		<u>—</u>

(1) (2) (3) – See notes on slide 38.

# Reconciliation of Net Income to Adjusted EBITDA <sup>(1)</sup>

(in millions, except per share data)	2013									
	Q1		Q2		Q3		Q4		Full Year	
	Total	Per Share	Total	Per Share						
<b>Net income</b>	\$ 65.9		\$ 179.0		\$ 72.3		\$ 64.2		\$ 381.4	
Loss (income) from disc ops, net of tax, attributable to HealthSouth	0.4		(0.1)		0.9		(0.1)		1.1	
Net income attributable to noncontrolling interests	(14.6)		(13.8)		(14.1)		(15.3)		(57.8)	
<b>Income from continuing operations attributable to HealthSouth <sup>(2)</sup></b>	51.7	\$ 0.48	165.1	\$ 1.66	59.1	\$ 0.59	48.8	\$ (0.31)	324.7	\$ 2.59
Gov't, class action, and related settlements	—		(2.0)		(21.3)		(0.2)		(23.5)	
Pro fees - acct, tax, and legal	1.4		2.2		4.2		1.7		9.5	
Provision for income tax expense (benefit)	33.5		(86.5)		35.2		30.5		12.7	
Interest expense and amortization of debt discounts and fees	24.2		24.4		25.3		26.5		100.4	
Depreciation and amortization	22.1		23.1		24.3		25.2		94.7	
Loss on early extinguishment of debt	—		—		—		2.4		2.4	
Other, including net noncash loss on disposal of assets	0.1		1.7		2.5		1.6		5.9	
Stock-based compensation expense	6.3		6.5		6.2		5.8		24.8	
<b>Adjusted EBITDA <sup>(1)</sup></b>	\$ 139.3		\$ 134.5		\$ 135.5		\$ 142.3		\$ 551.6	
<b>Weighted average common shares outstanding:</b>										
Basic		94.0		86.1		86.2		86.4		88.1
Diluted		107.1		99.8		100.4		100.8		102.1

(1) (2) – See notes on slide 38.

## Reconciliation Notes for Slides 35-37

1. Adjusted EBITDA is a non-GAAP financial measure. The Company's leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth.
2. Per share amounts for each period presented are based on diluted weighted average shares outstanding unless the amounts are antidilutive, in which case the per share amount is calculated using the basic share count after subtracting the quarterly dividend on the convertible perpetual preferred stock, income allocated to participating securities, and the repurchase premium on shares of preferred stock. The difference in shares between the basic and diluted shares outstanding is primarily related to the convertible senior subordinated notes and our convertible perpetual preferred stock.
3. HealthSouth acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased HealthSouth's ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method to a consolidated entity effective June 1, 2014.

# Net Cash Provided by Operating Activities Reconciled to Adjusted EBITDA

(Millions)	Q3		9 months		Full Year	
	2014	2013	2014	2013	2013	2012
<b>Net cash provided by operating activities</b>	\$ 139.6	\$ 142.6	\$ 374.7	\$ 369.4	\$ 470.3	\$ 411.5
Provision for doubtful accounts	(8.2)	(8.0)	(25.0)	(22.4)	(26.0)	(27.0)
Professional fees—accounting, tax, and legal	4.0	4.2	7.6	7.8	9.5	16.1
Interest expense and amortization of debt discounts and fees	27.8	25.3	83.5	73.9	100.4	94.1
Equity in net income of nonconsolidated affiliates	1.9	2.0	8.8	8.2	11.2	12.7
Net income attributable to noncontrolling interests in continuing operations	(14.7)	(14.1)	(44.3)	(42.5)	(57.8)	(50.9)
Amortization of debt discounts and fees	(3.2)	(1.0)	(9.5)	(3.0)	(5.0)	(3.7)
Distributions from nonconsolidated affiliates	(2.9)	(4.6)	(9.4)	(9.6)	(11.4)	(11.0)
Current portion of income tax expense	3.2	2.5	9.8	3.0	6.3	5.9
Change in assets and liabilities	(0.8)	(14.4)	43.7	21.8	48.9	58.1
Net premium (received) paid on bond issuance/redemption	(6.3)	—	(6.3)	—	1.7	1.9
Cash (provided by) used in operating activities of discontinued operations	(0.2)	1.2	1.0	1.4	1.9	(2.0)
Other	(0.2)	(0.2)	2.2	1.3	1.6	0.2
<b>Adjusted EBITDA</b>	<b>\$ 140.0</b>	<b>\$ 135.5</b>	<b>\$ 436.8</b>	<b>\$ 409.3</b>	<b>\$ 551.6</b>	<b>\$ 505.9</b>